Amgen developed a humanized monoclonal antibody directed against RANKL (denosumab), which has become a major therapeutic for the treatment of osteoporosis (Prolia ®) and bone cancer (Xgeva®)[7-9]. This evidence concerns the gene TNFSF11 and osteoporosis.